Welcome to our dedicated page for Aligos Therapeutics SEC filings (Ticker: ALGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the real story inside a clinical-stage biotech filing can feel like wading through lab notebooks. Aligos Therapeutics’ 10-K packs pages of R&D spend, trial readouts, and licensing clauses that drive its cash runway. Stock Titan decodes every line so you can spot pivotal disclosures without parsing dense scientific language.
Our AI reads each Aligos Therapeutics annual report 10-K simplified, flags pipeline milestones in the quarterly earnings report 10-Q filing, and translates 8-K material events explained within minutes of hitting EDGAR. Need to monitor Aligos Therapeutics insider trading Form 4 transactions? Get Aligos Therapeutics Form 4 insider transactions real-time alerts and see executive stock transactions Form 4 alongside clean charts of option grants, all in one place.
Whether you are comparing cash burn across trials, checking the Aligos Therapeutics proxy statement executive compensation, or seeking Aligos Therapeutics earnings report filing analysis, our platform delivers:
- AI-powered summaries that answer “understanding Aligos Therapeutics SEC documents with AI.”
- Real-time feeds for every 10-K, 10-Q, 8-K, S-3, and more.
- Contextual explanations linking hepatitis B capsid data and THR-β MASH results directly to valuation drivers.
No more manual downloads. Searchable tagging lets you ask natural questions like “Where can I review the next Aligos Therapeutics quarterly earnings report 10-Q filing?” and receive instant answers. From clinical trial obligations to Aligos Therapeutics SEC filings explained simply, Stock Titan turns complex biotech disclosures into actionable insights you can trust.
Aligos Therapeutics (ALGS) filed a routine Form 4 disclosing that director Carole Nuechterlein received a stock option grant for 5,860 common shares on 06/25/2025 at an exercise price of $7.63 per share. The option will vest 100% on the earlier of the first anniversary of the grant date or immediately prior to the company’s 2026 annual shareholders meeting, contingent upon her continued board service.
No shares were bought or sold and no other material transactions or changes in beneficial ownership were reported.
Aligos Therapeutics (NASDAQ:ALGS) submitted a routine Form 4 detailing an equity award to director James P. Scopa. On 25-Jun-2025 he received a stock option grant for 5,860 shares at an exercise price of $7.63 per share. The option vests 100% on the earlier of the first anniversary of the grant date or immediately before the company’s 2026 annual meeting and carries an expiration date of 25-Jun-2035. Following the transaction the director beneficially owns 5,860 derivative securities. No common shares were sold or otherwise disposed of, and the filing does not indicate any change in the company’s financial condition or strategy.
Aligos Therapeutics (NASDAQ:ALGS) filed a routine Form 4 reporting a new stock-option grant to director Peter Hirth.
The filing shows Mr. Hirth received 5,860 stock options with an exercise price of $7.63 per share on June 25 2025. The options vest 100 % on the earlier of the first anniversary of the grant date or immediately before the company’s 2026 annual meeting, contingent on continued board service. Following the grant, Mr. Hirth beneficially owns 5,860 derivative securities; no non-derivative share transactions were reported.
No sales, purchases of common stock, or other material changes in ownership were disclosed. The transaction appears to be a standard director compensation award and does not, by itself, indicate a material change in Aligos Therapeutics’ financial outlook or governance.
Aligos Therapeutics (NASDAQ: ALGS) submitted a routine Form 4 disclosing a standard equity compensation grant to director Heather Preston. On 06/25/2025, Preston received 5,860 non-qualified stock options with an exercise price of $7.63 per share, matching the prevailing market price. The award vests 100 percent on the earlier of the first anniversary of the grant or immediately before the 2026 annual shareholder meeting, conditional on continued board service. No common shares were purchased or sold, and Preston’s beneficial ownership now reflects only the newly issued derivative securities.
Aligos Therapeutics (NASDAQ: ALGS) filed a routine Form 4 disclosing an insider stock-option grant to director Margarita Chavez.
On June 25 2025, Chavez received an option to purchase 5,860 common shares at an exercise price of $7.63. The option vests 100 % on the earlier of the first anniversary of the grant or immediately prior to the company’s 2026 annual meeting, and expires on June 25 2035. No shares were bought or sold in the open market, and beneficial ownership remains unchanged except for the new option award.
The filing appears to reflect standard board compensation and does not indicate any material change in corporate strategy, financial condition, or insider sentiment.
Aligos Therapeutics (NASDAQ:ALGS) filed a routine Form 4 disclosing an insider grant. On June 25 2025, director Bridget A. Martell was awarded 5,860 stock options with a strike price of $7.63 per share. The options vest 100 % on the earlier of the first anniversary of the grant date or immediately before the 2026 annual shareholder meeting and expire on June 25 2035. After the transaction, Martell beneficially owns 5,860 derivative securities. No open-market purchases or sales of ALGS common stock were reported.
Aligos Therapeutics (Nasdaq:ALGS) filed an 8-K disclosing results of its June 25, 2025 Annual Meeting.
- Authorized share increase: voting common stock rises from 20 million to 100 million; non-voting common stock from 0.8 million to 15.8 million (Item 5.03).
- Equity plan expansion: 2020 Incentive Award Plan enlarged by 1,000,000 shares (Item 5.02).
- All proposals passed with c.~87% support; three Class II directors re-elected and Ernst & Young ratified as auditor (Item 5.07).
- Shares outstanding on record date: 5,314,801.
The amendments give management broad capacity to issue new equity for financing or compensation, but materially raise dilution risk for existing holders. No financial results were reported.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
What is the primary focus of Aligos Therapeutics?
Which therapeutic areas does Aligos address?
What is ALG-000184 and its significance?
How does the THR-beta agonist candidate, ALG-055009, work?
What strategic collaborations has Aligos Therapeutics pursued?
How does Aligos differentiate itself in a competitive market?
Where is Aligos Therapeutics headquartered and when was it founded?
What are the long-term clinical development strategies of Aligos?
